The vast majority of trials have focused on RAS effectors, such as the PI3K/AKT/mTOR or RAS/REF/MEK pathways, and unfortunately have failed to show clinical benefit, illustrating the need to identify other pathways as important targets for MPNST drug development. This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.